Quarterly ResultMay 4, 2026, 04:26 PM
Oric Pharma Q1 Net Loss $(35.77)M; EPS $(0.34)
AI Summary
Oric Pharmaceuticals reported a net loss of $(35.77) million for the first quarter of 2026, an increase from $(30.02) million in the prior year, while net loss per share improved to $(0.34) from $(0.42). The company's cash and cash equivalents rose to $56.40 million, supported by $59.9 million in net proceeds from at-the-market offerings during the quarter. Research and development expenses increased, reflecting continued investment in its lead clinical programs, rinzimetostat and enozertinib, following a strategic pipeline prioritization and workforce reduction in late 2025.
Key Highlights
- Net loss for Q1 2026 was $(35.77) million, compared to $(30.02) million in Q1 2025.
- Net loss per share for Q1 2026 was $(0.34), compared to $(0.42) in Q1 2025.
- Research and development expenses increased to $31.44 million in Q1 2026 from $24.64 million in Q1 2025.
- Cash and cash equivalents increased to $56.40 million as of March 31, 2026, from $45.67 million at December 31, 2025.
- Total assets grew to $436.76 million as of March 31, 2026, from $408.89 million at December 31, 2025.
- Total stockholders' equity increased to $415.56 million as of March 31, 2026, from $384.36 million at December 31, 2025.
- Net cash used in operating activities was $(32.44) million in Q1 2026, slightly down from $(32.53) million in Q1 2025.
- Raised net proceeds of approximately $59.9 million from ATM offerings in Q1 2026.
Price Impact
More from ORIC